Le Lézard
Classified in: Health
Subjects: PDT, AVO

Americans for Prosperity Launches New Ad Campaign in Support of the ACCESS Act


Legislation from Congressman Greg Steube and Congresswoman Kat Cammack allows low-income Americans to put a portion of their ACA cost-sharing reduction (CSR) subsidies into a health savings account, expanding access to more affordable and personalized options.

ARLINGTON, Va., Feb. 1, 2024 /PRNewswire/ -- Today, Americans for Prosperity launched a digital ad campaign to promote H.R. 5608, The ACCESS Act. This innovative legislation led by U.S. Reps. Greg Steube (FL-17) and Kat Cammack (FL-3) would allow lower-income Americans on ACA plans to put a portion of their CSR subsidies into a health savings account. This increases access to affordable health care and empowers individuals with more options to choose from.

A :30 video and a series of display ads that promote the legislation will run for the next six months on digital platforms in the Washington, D.C. metro area and dozens of congressional districts represented by key U.S. House lawmakers.

Click here to watch AFP's new video on the ACCESS Act

Click here to view a sample banner ad.

The ACCESS Act would establish a tax-free health savings account (HSA) option for about 5 million lower-income families eligible for CSRs under the Affordable Care Act. Participants could use their HSA funds to purchase medical items and services directly, including those not covered by their insurance, giving them greater access to needed care.

The bill would also reform the CSR payment program to permanently appropriate money for it, something Congress has so far neglected to do. Thanks to this provision, the bill would make the program more efficient and save taxpayers an estimated $29 billion over ten years, according to the nonpartisan Congressional Budget Office.

"The ACCESS Act is a needed relief for millions of lower-income families who are stuck in costly, one-size-fits-all ACA plans and could use more personalized options to pick from," said Dean Clancy, senior health policy fellow at Americans for Prosperity. "Being able to select a pre-funded health savings account would empower Americans with new choices that will allow them to upgrade from substandard government health care to more personalized solutions that better meet their needs. We applaud Congressman Steube and Congresswoman Cammack for sponsoring this innovative legislation that funds people and families ? not the system. We urge Congress to pass the ACCESS Act as soon as possible."

Click here to learn more about The ACCESS Acthealth savings accounts, and AFP's vision for health care reform, the Personal Option.

SOURCE Americans for Prosperity


These press releases may also interest you

at 20:00
Zimmerman Reed announced today that the United States and the State of California reached a $7 million settlement with ReNew Health Group LLC, ReNew Health Consulting Services LLC, and its owner-CEO and its COO to resolve False Claims Act allegations...

at 19:15
In a recent round of grant awards, the STRONG STAR Consortium based at The University of Texas Health Science Center at San Antonio (UT Health San Antonio)...

at 18:50
Ontario's forest firefighters will soon have the same presumptive WSIB coverage that urban firefighters do. Like urban firefighters, forest firefighters are at a higher risk of cancer, heart disease and heart injuries, and post-traumatic stress...

at 18:49
A final FDA rule regulating laboratory-developed tests (LDTs) as medical devices does not address serious concerns raised by ARUP Laboratories and the clinical laboratory community, and the company's stance on the rule has not changed, CEO Andy...

at 18:45
Pfizer Inc. and Genmab A/S today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with...

at 18:45
Genmab A/S and Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or...



News published on and distributed by: